Under construction – not a live service
Sign in
Taking people in United StatesNo phase

At-Home Heart Rehab for Young Cancer Survivors at Heart Failure Risk

Tests an at-home heart exercise program in teen cancer survivors at risk of heart failure.

Plain-language title generated from the registry record
Registry title: At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure

Key facts

Where
Los Angeles, United StatesSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 21 years old?

Source: NCT06826534, who can take part

Where in United States

  • Children's Hospital Los AngelesLos Angeles, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Children's Hospital Los Angeles
Trial code
NCT06826534
Record updated
14 February 2025
Original description
The goal of this clinical trial is to explore the impact that an at-home cardio-oncology rehabilitation (CORE) may have on short-term cardiovascular fitness and psychosocial wellness in pediatric cancer survivors. The main question it aims to answer areRead full original descriptionShow less

At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure

The goal of this clinical trial is to explore the impact that an at-home cardio-oncology rehabilitation (CORE) may have on short-term cardiovascular fitness and psychosocial wellness in pediatric cancer survivors. The main question it aims to answer are

* To evaluate the efficacy of an at-home CORE model on short-term cardiovascular fitness and psychosocial wellbeing in adolescent cancer survivors. * To evaluate the exercise adherence rate among adolescents at risk for heart failure and assess barriers to compliance. * To explore which specific CORE resources are of most value to patients in creating sustainable healthy lifestyle modifications. * Hypothesis: Pediatric cancer survivors who implement exercise and dietary recommendations will demonstrate improvement in cardiovascular fitness and general wellness. A multidisciplinary team approach can facilitate adherence to a moderately rigorous exercise prescription, and thus enhance the health benefits of a CORE program at CHLA.

Participants will undergo cardiovascular studies and a quality-of-life survey prior to exercise intervention, and at the end of the 6-month study period.

Inclusion: Patients aged of 10-21 years at enrollment; Parent/legal guardian available for consent (if applicable), and patient available for assent and consent; History of anthracycline exposure +/- radiation; Currently in remission, with at least 6 months off chemotherapy; Able to perform CPET; Baseline CPET with VO2 <80% (at start of study, or CPET at CHLA after January 2020); Smartphone compatible with Fitbit (own or parent/legal guardian's); Ability to complete and send diary and Fitbit information on a weekly basis; Ability to participate in monthly virtual check-in visits; Baseline activity prior to intervention <30min/day, 2x/week.

Exclusion: No other primary medical diagnosis (e.g., Down Syndrome, Wolff-Parkinson-White Syndrome, congenital heart disease) or history of cardiothoracic surgery; Contraindication to moderate activity (>3 METs). Examples include history of malignant arrhythmias, exercise-induced syncope, severe symptoms of HF (NYHA IV, ACC/AHA Stage D); Unable to perform CPET, echocardiogram, EKG, or obtain laboratory studies; Inability to obtain consent/assent; Unable to accurately perform quality of life survey independently; Unable to perform mild activity for at least 0.5h/day and at least 2x/week; Unable to come to hospital for study visits at 0 and 6 months; Unable to complete study-related surveys; Unable to complete and send diary and Fitbit information on a weekly basis; Unable to check-in monthly on virtual platform; On beta blockade; Pregnancy.

ClinicalTrials.gov NCT06826534